Therapeutic Asset Ratings
12,939 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Artesunate
Cervical Intraepithelial Neoplasia
UNC Lineberger Comprehensive Cancer Center
P1
CC
(47)
Asundexian
Acute Myocardial Infarction
Bayer
P1
CC
(47)
Asundexian
Liver Disorder
Bayer
P1
CC
(47)
Asundexian
Thrombotic Disease
Bayer
P1
CC
(47)
Atezolizumab
Gastrointestinal Neuroendocrine Tumors
Arbele Pty Ltd
P1
CC
(47)
Atirmociclib
Healthy Adults
Pfizer
P1
CC
(47)
Avapritinib
Non-resectable Advanced Solid Tumors
Blueprint Medicines Corporation
P1
CC
(47)
Axitinib
HER-2 Protein Overexpression
Lynkcell Europe
P1
CC
(47)
azd2693
Liver Disorder
AstraZeneca
P1
CC
(47)
azd7503
Fatty Liver, Nonalcoholic
AstraZeneca
P1
CC
(47)
bb-025
Pharmacodynamics
Basking Biosciences, Inc.
P1
CC
(47)
bb-025
Pharmacokinetics
Basking Biosciences, Inc.
P1
CC
(47)
bb-031
Pharmacodynamics
Basking Biosciences, Inc.
P1
CC
(47)
bb-031
Pharmacokinetics
Basking Biosciences, Inc.
P1
CC
(47)
bi 765063
Head And Neck Squamous Cell Carcinoma
Boehringer Ingelheim
P1
CC
(47)
Binimetinib
KRAS Gene Mutation
Taiho Oncology, Inc.
P1
CC
(47)
Bms-907351
Triple-Negative Breast Carcinoma
National Cancer Institute (NCI)
P1
CC
(47)
BMS-986345
Lymphoid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
P1
CC
(47)
BMS-986369
Liver Disorder
Celgene
P1
CC
(47)
Bocidelpar
Liver Disorder
Astellas Pharma Global Development, Inc.
P1
CC
(47)
c106
Tolerance
Vicore Pharma AB
P1
CC
(47)
Cabotamig
Digestive System Neuroendocrine Neoplasm
Arbele Pty Ltd
P1
CC
(47)
CAFFEINE
Liver Disorder
AstraZeneca
P1
CC
(47)
Calaspargase Pegol
Relapsed/Refractory Leukemias
Syndax Pharmaceuticals
P1
CC
(47)
Camizestrant
ER-positive, HER2-negative Breast Cancer
AstraZeneca
P1
CC
(47)
Showing 251 to 275 of 12,939 assets
Previous
Page 11 of 518
Next
